RESUMEN
BACKGROUND: The first Covid-19 pandemic affected the epidemiology of several diseases. A general reduction in the emergency department (ED) accesses was observed during this period, both in adult and pediatric contexts. METHODS: This retrospective study was conducted on the behalf of the Italian Society of Pediatric Nephrology (SINePe) in 17 Italian pediatric EDs in March and April 2020, comparing them with data from the same periods in 2018 and 2019. The total number of pediatric (age 0-18 years) ED visits, the number of febrile urinary tract infection (UTI) diagnoses, and clinical and laboratory parameters were retrospectively collected. RESULTS: The total number of febrile UTI diagnoses was 339 (73 in 2020, 140 in 2019, and 126 in 2018). During the first Covid-19 pandemic, the total number of ED visits decreased by 75.1%, the total number of febrile UTI diagnoses by 45.1%, with an increase in the UTI diagnosis rate (+ 121.7%). The data collected revealed an increased rate of patients with two or more days of fever before admission (p = 0.02), a significant increase in hospitalization rate (+ 17.5%, p = 0.008) and also in values of C reactive protein (CRP) (p = 0.006). In 2020, intravenous antibiotics use was significantly higher than in 2018 and 2019 (+ 15%, p = 0.025). Urine cultures showed higher Pseudomonas aeruginosa and Enterococcus faecalis percentages and lower rates of Escherichia coli (p = 0.02). CONCLUSIONS: The first wave of the Covid-19 pandemic had an essential impact on managing febrile UTIs in the ED, causing an absolute reduction of cases referring to the ED but with higher clinical severity. Children with febrile UTI were more severely ill than the previous two years, probably due to delayed access caused by the fear of potential hospital-acquired Sars-Cov-2 infection. The possible increase in consequent kidney scarring in this population should be considered.
Asunto(s)
COVID-19 , Infecciones Urinarias , Adolescente , Adulto , Antibacterianos/uso terapéutico , Proteína C-Reactiva , COVID-19/epidemiología , Niño , Preescolar , Brotes de Enfermedades , Servicio de Urgencia en Hospital , Escherichia coli , Fiebre/tratamiento farmacológico , Fiebre/epidemiología , Fiebre/etiología , Humanos , Lactante , Recién Nacido , Pandemias , Estudios Retrospectivos , SARS-CoV-2 , Infecciones Urinarias/diagnósticoRESUMEN
BACKGROUND: This study aimed to evaluate the effect of oral dexamethasone in reducing kidney scars in infants with a first febrile urinary tract infection (UTI). METHODS: Children aged between 2 and 24 months with their first presumed UTI, at high risk for kidney scarring based on procalcitonin levels (≥1 ng/mL), were randomly assigned to receive dexamethasone in addition to routine care or routine care only. Kidney scars were identified by kidney scan at 6 months after initial UTI. Projections of enrollment and follow-up completion showed that the intended sample size could not be reached before funding and time to complete the study ran out. An amendment to the protocol was approved to conduct a Bayesian analysis. RESULTS: We randomized 48 children, of whom 42 had a UTI and 18 had outcome kidney scans (instead of 128 planned). Kidney scars were found in 0/7 and 2/11 patients in the treatment and control groups respectively. The probability that dexamethasone could prevent kidney scarring was 99% in the setting of an informative prior probability distribution (which fully incorporated in the final inference the information on treatment effect provided by previous studies) and 98% in the low-informative scenario (which discounted the prior literature information by 50%). The probabilities that dexamethasone could reduce kidney scar formation by up to 20% were 61% and 53% in the informative and low-informative scenario, respectively. CONCLUSIONS: Dexamethasone is highly likely to reduce kidney scarring, with a more than 50% probability to reduce kidney scars by up to 20%. TRIAL REGISTRATION NUMBER: EudraCT number: 2013-000388-10; registered in 2013 (prospectively registered) A higher resolution version of the Graphical abstract is available as Supplementary information.
Asunto(s)
Dexametasona , Fiebre , Glomerulonefritis , Infecciones Urinarias , Administración Oral , Teorema de Bayes , Preescolar , Dexametasona/administración & dosificación , Fiebre/tratamiento farmacológico , Glomerulonefritis/prevención & control , Humanos , Lactante , Tamaño de la Muestra , Resultado del Tratamiento , Infecciones Urinarias/tratamiento farmacológicoRESUMEN
BACKGROUND: Cardiovascular diseases and insufficient levels of vitamin D are risk factors for adverse surgical outcomes, and they are both commonly present among older adults undergoing orthopaedic surgery. Giving the cardiovascular effects of vitamin D, pre-operative diagnosis of hypovitaminosis D would be a valuable step for the implementation of supplementation protocols. We investigated if the normalization of serum 25 [OH] D could ameliorate cardiac performance of older adults suffering from cardiovascular diseases. METHODS: We enrolled 47 older adults scheduled for major orthopaedic surgery and suffering from hypovitaminosis D. Patients underwent 6-months calcifediol supplementation with a starting dose at first post-operative day of 50 µg/die in liquid preparation. Down-titration to 20 µg/die at 3-months assessment was planned. Cardiac performance was evaluated by measuring left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) during pre-operative assessments and at 1-month, 3-months, 6-months follow-ups. RESULTS: Six months of calcifediol supplementation were associated with a significant improvement of both LVEF (+ 3.94%; 95% CI: -4.0789 to -0.8232; P < 0.01) and GLS (+ 18.56%; Z = -5.895; P < 0.0001). CONCLUSIONS: Calcifediol supplementation normalized serum 25 [OH] D concentration after 1-month treatment. GLS offered better insights into myocardial contractile amelioration than LVEF, thus being useful for detecting earlier subclinical changes that may anticipate hemodynamic modifications.
RESUMEN
El aneurisma de la aorta abdominal es una enfermedad de mal pronóstico, de corta expectación de la vida, incluso en pacientes asintomáticos. La tercera parte fallece dentro del año de efectuado el diagnóstico y librado a su evolución espontánea. Más del 90 por ciento de los portadores de la afección no sobreviven más de 5 años. Cuando aparecen signos de aplicación se produce la muerte en pocas horas o días. El diagnóstico de los aneurismas de la aorta abdominal se basa clásicamente en la exploración clínica, radiografía simple y laangiografía abdominal. Sin embargo, un considerable número de ellos escapan al diagnóstico debido a varios factores. Por otra parte, al depender el pronóstico de los aneurismas de su tamaño y ritmo de crecimiento, se precisa una valoración exacta y a veces reiterada de su volumen real. Tampoco aquí los métodos clásicosse muestran idóneos para conseguir en todos los casos estos objetivos que en definitiva condicionan la indicación quirúrgica absoluta. Modernamente con la utilización de la ecosonografía en la exploración abdominal, el eco-Doppler, la tomografía axial computarizada, la angiografía con substracción digital y la resonancia magnética, se puede diagnosticar la forma, tamaño extensión, disección y relación topográfica con órganos vecinos. La ecosonografía abdominal ofrece actualmente una solución a estos problemas al representar un método de diagnóstico quereúne a la vez la ventaja de inocuo, incruento, indoloro, económico, de aplicaciónsencilla y con posibilidades ilimitadas de repetición. Al mismo tiempo proporciona una medida de gran exactitud de sus dimensiones verdaderas e incluso detecta su evolución hacia la trombosis fisuración o ruptura